Central nervous system circuitry involved in the hyperinsulinism syndrome

Neuroendocrinology

Volumn 84, Issue 4, 2007, Pages 222-234

  Lechin, Fuad ^a   Van Der Dijs, Bertha ^a  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

Autoimmune diseases; Bed nucleus stria terminalis; Catecholamines; Dorsal raphe nucleus; Glucagon; Hyperinsulinism; Median raphe nucleus; Neuroimmune interactions; Serotonin

Indexed keywords

ADIPONECTIN; ADRENALIN; ALPHA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; GHRELIN; GLUCAGON; GLUCOSE; GROWTH HORMONE; INCRETIN; INSULIN; LEPTIN; NORADRENALIN; RESISTIN; SOMATOSTATIN; VISFATIN;

AUTONOMIC NERVOUS SYSTEM FUNCTION; BREAST CYST; CELL FUNCTION; CELL STIMULATION; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; DISEASE ASSOCIATION; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEPATOBILIARY SYSTEM; HORMONAL REGULATION; HUMAN; HYPERINSULINISM; HYPERINSULINISM SYNDROME; HYPERTENSION; HYPOTHALAMUS; INSULA; INSULIN BLOOD LEVEL; INSULIN RELEASE; MEDIAN RAPHE NUCLEUS; NORADRENALIN RELEASE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY CYST; PANCREAS; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PANCREAS ISLET DELTA CELL; PRIORITY JOURNAL; RHEUMATIC DISEASE; SCHIZOPHRENIA; SEROTONINERGIC NERVE CELL; SHORT SURVEY; SLEEP DISORDER; SOMATOSTATIN CELL; STRESS; SYMPATHETIC TONE;

ANIMALS; BLOOD GLUCOSE; CENTRAL NERVOUS SYSTEM; GASTROINTESTINAL HORMONES; GLUCAGON; HOMEOSTASIS; HUMANS; HYPERINSULINISM; INSULIN; NEURAL PATHWAYS; NEUROSECRETORY SYSTEMS;

EID: 33847777497     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098005     Document Type: Short Survey

References (109)

1. Borg WP, Sherwin RS, During MJ, Borg MA, Shulman GI: Local ventromedial hypothalamus glucopenia triggers counterregulatory hormone release. Diabetes 1995;44:180-184.
2. A receptors in the ventromedial hypothalamus further stimulates glucagon and sympathoadrenal but not the hypothalamo-pituitary-adrenal response to hypoglycemia. Diabetes 2006;55:1080-1087.
3. Lechin F: The effect of secretin on serum potassium. Acta Physiol Latinoam 1962;12:370-374.
4. Lechin F: Secretina y potasio serico. GEN 1963;17:347-351.
5. Lechin F, van der Dijs B: Glucose disposal. Lancet 1964;ii:1122.
6. Lechin F, Coll-Garcia E, van der Dijs B: Efectos de la serotonina (5-HT) sobre la secreción de insulina por islotes aislados incubados in vitro. Acta Cient Venez 1973;24:32-40.
7. Lechin F, Benshimol A, van der Dijs B, Gruber JM, Levy A: Histalog and secretin effects on serum electrolytes. Influence of pancreatectomy and gastrectomy. Acta Gastroenterol Latinoam 1970;2:9-18.
8. Lechin F, Coll-Garcia E, van der Dijs B: Efectos de la administración intraportal de serotonina (5-HT), sobre los niveles de glucosa e insulina inmuno-reactiva (IRI), de la vena pancreato-duodenal del perro. Acta Cient Venez 1973;24:19-24.
9. Lechin F, Coll-Garcia E, van der Dijs B, Peña F, Bentolila A, Rivas C: The effect of serotonin (5-HT) on insulin secretion. Acta Physiol Latinoam 1975;25:339-346.
10. McIntyre N, Holdsworth CD, Turner DS: Intestinal factors in the control of insulin secretion. J Clin Endocrinol Metab 1965;25:1317-1324.
11. Dupre J, Beck JC: Stimulation of release of insulin by an extract of intestinal mucosa. Diabetes 1966;15:555-559.
12. Dupre J, Rojas L, White JJ, Unger RH, Beck JC: Effects of secretin on insulin and glucagon in portal and peripheral blood in man. Lancet 1966;ii:26-27.
13. Chisholm DJ, Young JD, Lazarus L: The gastrointestinal stimulus to insulin release. I. Secretin. J Clin Invest 1969;48:1453-1460.
14. Lechin F: Intestinal hormones and plasma insulin. Lancet 1966;ii:35-36.
15. Lechin F: Control gastrointestinal de la secreción de insulina; paper presented for promotion to titular professor. Caracas, Imprenta Universitaria, UCV, 1972.
16. Lechin F, van der Dijs B, Orozco B: Cholecystokinin (CCK) and secretin and pancreatic secretion of insulin and glucagon. Dig Dis Sci 2002;47:2422-2423.
17. Lechin F, Coll-Garcia E, van der Dijs B, Bentolila A, Peña F, Rivas C: Effects of captivity on glucose tolerance in dogs. Experientia 1979;35:876-877.
18. Lechin F, van der Dijs B, Hernandez-Adrian G: Dorsal raphe vs. median raphe serotonergic antagonism. Anatomical, physiological, behavioral, neuroendocrinological, neuropharmacological and clinical evidences: relevance for neuropharmacological therapy. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:565-585.
19. Lechin F, Coll-Garcia E, van der Dijs B, Bentolila A, Peña F, Rivas C: The effects of dopaminergic blocking agents on the glucose tolerance test in 6 humans and 6 dogs. Experientia 1979;35:886-887.
20. Lechin F, van der Dijs B: Haloperidol and insulin release. Diabetologia 1981;20:78-79.
21. Lechin F, van der Dijs B: Intestinal pharmacomanometry and glucose tolerance: evidence for two antagonistic dopaminergic mechanisms in the human. Biol Psychiatry 1981;16:969-986.
22. Lechin F, van der Dijs B: Effects of dopaminergic blocking agents on distal colon motility. J Clin Pharmacol 1979;19:617-625.
23. Lechin F, van der Dijs B, Lechin M, Baez S, Jara H, Lechin A, Orozco B, Rada I, Cabrera A, Jimenez V: Effects of an oral glucose load on plasma neurotransmitters in humans: involvement of REM sleep? Neuropsychobiology 1992;26:4-11.
24. Lechin F, van der Dijs B, Lechin M, Jara H, Lechin A, Baez S, Orozco B, Rada I, Cabrera A, Arocha L, Jiménez V, Leon G: Plasma neurotransmitters throughout an oral glucose tolerance test in essential hypertension. Clin Exp Hypertens 1993;15:209-240.
25. Lechin F, van der Dijs B, Orozco B, Baez S, Rada I, Garcia Z, Jara H, Lechin AE, Lechin ME: Plasma neurotransmitters, blood pressure and heart rate during supine-resting, orthostasis and moderate exercise stress test in healthy humans before and after parasympathetic blockade with atropine. Res Commun Biol Psychol Psychiatry 1996;21:55-72.
26. Lechin F, van der Dijs B: Glucose tolerance, non-nutrient drink and gastrointestinal hormones. Gastroenterology 1981;80:216-217.
27. Lechin F, van der Dijs B, Lechin AE: Circulating serotonin, catecholamines and CNS circuitry related to some cardiorespiratory and vascular disorders. J Appl Res 2005;5:605-621.
28. Lechin F, van der Dijs B, Lechin AE: Neural sympathetic activity in essential hypertension. Hypertension 2004;44:e3-e4.
29. Samols E, Stagner JI: Intra-islet regulation. Am J Med 1988;85:31-35.
30. Samols E, Stagner JI, Ewart RB, Marks V: The order of islet microvascular cellular perfusion is B→A→D in the perfused rat pancreas. J Clin Invest 1988;82:350-353.
31. Oskarsson P, Adamson U, Sjobom NC, Lins PE: Long-term follow-up of insulin-dependent diabetes mellitus patients with recurrent episodes of severe hypoglycaemia. Diabetes Res Clin Pract 1999;44:165-174.
32. Duttaroy A, Zimliki CL, Gautam D, Cui Y, Mears D, Wess J: Muscarinic stimulation of pancreatic insulin and glucagon release is abolished in m3 muscarinic acetylcholine receptor-deficient mice. Diabetes 2004;53:1714-1720.
33. Ma X, Zhang Y, Gromada J, Sewing S, Berggren PO, Buschard K, Salehi A, Vikman J, Rorsman P, Eliasson L: Glucagon stimulates exocytosis in mouse and rat pancreatic alpha-cells by binding to glucagon receptors. Mol Endocrinol 2005;19:198-212.
34. Wendt A, Birnir B, Buschard K, Gromada J, Salehi A, Sewing S, Rorsman P, Braun M: Glucose inhibition of glucagon secretion from rat alpha-cells is mediated by GABA released from neighboring beta-cells. Diabetes 2004;53:1038-1045.
35. Xu E, Kumar M, Zhang Y, Ju W, Obata T, Zhang N, Liu S, Wendt A, Deng S, Ebina Y, Wheeler MB, Braun M, Wang Q: Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system. Cell Metab 2006;3:47-58.
36. Quesada I, Todorova MG, Soria B: Different metabolic responses in alpha-, beta-, and delta-cells of the islet of Langerhans monitored by redox confocal microscopy. Biophys J 2006;90:2641-2650.
37. Starke A, Imamura T, Unger RH: Relationship of glucagon suppression by insulin and somatostatin to the ambient glucose concentration. J Clin Invest 1987;79:20-24.
38. Ludvigsen E, Stridsberg M, Taylor JE, Culler MD, Oberg K, Janson ET, Sandler S: Regulation of insulin and glucagon secretion from rat pancreatic islets in vitro by somatostatin analogues. Regul Pept, in press.
39. Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, Cui L, Obici S, Tang B, Holst JJ, Fledelius C, Johansen PB, Rossetti L, Jelicks LA, Serup P, Nishimura E, Charron MJ: Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci USA 2003;100:1438-1443.
40. Takahashi T, Fujishima M, Tsuchida S, Enoki M, Takada G: Johanson-Blizzard syndrome: loss of glucagon secretion response to insulin-induced hypoglycemia. J Pediatr Endocrinol Metab 2004;17:1141-1144.
41. Porte D Jr, Robertson RP: Control of insulin secretion by catecholamines, stress, and the sympathetic nervous system. Fed Proc 1973;32:1792-1796.
42. Robertson RP, Porte D Jr: Adrenergic modulation of basal insulin secretion in man. Diabetes 1973;22:1-8.
43. O'Driscoll L, Gammell P, Clynes M: Mechanisms associated with loss of glucose responsiveness in beta cells. Transplant Proc 2004;36:1159-1162.
44. Bendet N, Scapa E, Cohen O, Bloch O, Aharoni D, Ramot Y, Weiss M, Halevi A, Rapoport MJ: Enhanced glucose-dependent glucagon-like peptide-1 and insulin secretion in Crohn patients with terminal ileum disease is unrelated to disease activity or ileal resection. Scand J Gastroenterol 2004;39:650-656.
45. Lechin F, van der Dijs B, Lechin S, Vitelli G, Lechin ME, Cabrera A: Neurochemical, hormonal and immunological views of stress: clinical and therapeutic implications in Crohn's disease and cancer; in Velazco M (ed): Recent Advances in Clinical Pharmacology and Therapeutics. International Congress Series. Amsterdam, Excerpta Medica, 1989, vol 839, pp 57-70.
46. Lechin F, van der Dijs B, Lechin ME: Neuroendocrine-immune interactions; in Lechin F, van der Dijs B, Lechin ME (eds): Neurocircuitry and Neuroautonomic Disorders. Reviews and Therapeutic Strategies. Basel, Karger, 2002, pp 60-62.
47. Gibson TB, Lawrence MC, Gibson CJ, Vanderbilt CA, McGlynn K, Arnette D, Chen W, Collins J, Naziruddin B, Levy MF, Ehrlich BE, Cobb MH: Inhibition of glucose-stimulated activation of extracellular signal-regulated protein kinases 1 and 2 by epinephrine in pancreatic beta-cells. Diabetes 2006;55:1066-1073.
48. Ishihara H, Maechler P, Gjinovci A, Herrera PL, Wollheim CB: Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells. Nat Cell Biol 2003;5:330-335.
49. Kawabata A, Matsunami M, Tsutsumi M, Ishiki T, Fukushima O, Sekiguchi F, Kawao N, Minami T, Kanke T, Saito N: Suppression of pancreatitis-related allodynia/hyperalgesia by proteinase-activated receptor-2 in mice. Br J Pharmacol 2006;148:54-60.
50. Young JB, Rosa RM, Landsberg L: Dissociation of sympathetic nervous system and adrenal medullary responses. Am J Physiol 1984;247:E35-E40.
51. Koerner A, Kratzsch J, Kiess W: Adipocytokines: leptin - the classical, resistin - the controversical, adiponectin - the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005;19:525-546.
52. Elmquist JK, Elias CF, Saper CB: From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 1999;22:221-232.
53. Ahima RS, Saper CB, Flier JS, Elmquist JK: Leptin regulation of neuroendocrine systems. Front Neuroendocrinol 2000;21:263-307.
54. Ahima RS, Flier JS: Leptin. Annu Rev Physiol 2000;62:413-437.
55. Beltowski J: Apelin and visfatin: unique 'beneficial' adipokines upregulated in obesity? Med Sci Monit 2006;12:112-119.
56. Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M, Recasens M, Esteve E, Casamitjana R, Ricart W, Fernandez-Real JM: Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006;55:2871-2875.
57. Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M: The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006;49:1909-1914.
58. Wilkinson M, Wilkinson D, Wiesner G, Morash B, Ur E: Hypothalamic resistin immunoreactivity is reduced by obesity in the mouse: co-localization with alpha-melanostimulating hormone. Neuroendocrinology 2005;81:19-30.
59. Dominici FP, Argentino DP, Munoz MC, Miquet JG, Sotelo AI, Turyn D: Influence of the crosstalk between growth hormone and insulin signalling on the modulation of insulin sensitivity. Growth Horm IGF Res 2005;15:324-336.
60. Luo S, Luo J, Cincotta AH: Chronic ventromedial hypothalamic infusion of norepinephrine and serotonin promotes insulin resistance and glucose intolerance. Neuroendocrinology 1999;70:460-465.
61. Lechin F, van der Dijs B: Central nervous system circuitry and peripheral neural sympathetic activity responsible for essential hypertension. Curr Neurovasc Res 2006;3:307-325.
62. Liang Y, Luo S, Cincotta AH: Long-term infusion of norepinephrine plus serotonin into the ventromedial hypothalamus impairs pancreatic islet function. Metabolism 1999;48:1287-1289.
63. Cincotta AH, Luo S, Zhang Y, Liang Y, Bina KG, Jetton TL, Scislowski PW: Chronic infusion of norepinephrine into the VMH of normal rats induces the obese glucose-intolerant state. Am J Physiol Regul Integr Comp Physiol 2000;278:R435-R444.
64. Kahn BB, Flier JS: Obesity and insulin resistance. J Clin Invest 2000;106:473-481.
65. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L: Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981;30:219-225.
66. Christensen NJ: Acute effects of insulin on cardiovascular function and noradrenaline uptake and release. Diabetologia 1983;25:377-381.
67. Jansen AS, Hoffman JL, Loewy AD: CNS sites involved in sympathetic and parasympathetic control of the pancreas: a viral tracing study. Brain Res 1997;766:29-38.
68. Lechin F, van der Dijs B, Lechin A, Lechin M, Coll-Garcia E, Jara H, Cabrera A, Jimenez V, Gomez F, Tovar D, Rada I, Arocha L: Doxepin therapy for postprandial symptomatic hypoglycaemic patients: neurochemical, hormonal and metabolic disturbances. Clin Sci 1991;80:373-384.
69. Loewy AD, Marson L, Parkinson D, Perry MA, Sawyer WB: Descending noradrenergic pathways involved in the A5 depressor response. Brain Res 1986;386:313-324.
70. Gauthier P, Reis DJ, Nathan MA: Arterial hypertension elicited either by lesions or by electrical stimulations of the rostral hypothalamus in the rat. Brain Res 1981;211:91-105.
71. Gurtu S, Pant KK, Sinha JN, Bhargava KP: An investigation into the mechanism of cardiovascular responses elicited by electrical stimulation of locus coeruleus and subcoeruleus in the cat. Brain Res 1984;301:59-64.
72. Byrum CE, Guyenet PG: Afferent and efferent connections of the A5 noradrenergic cell group in the rat. J Comp Neurol 1987;261:529-542.
73. Drye RG, Baisden RH, Whittington DL, Woodruff ML: The effects of stimulation of the A5 region on blood pressure and heart rate in rabbits. Brain Res Bull 1989;24:33-39.
74. Clark FM, Yeomans DC, Proudfit HK: The noradrenergic innervation of the spinal cord: differences between two substrains of Sprague-Dawley rats determined using retrograde tracers combined with immunocytochemistry. Neurosci Lett 1991;125:155-158.
75. Dampney RA: Functional organization of central pathways regulating the cardiovascular system. Physiol Rev 1994;74:323-364.
76. Fenik V, Marchenko V, Janssen P, Davies RO, Kubin L: A5 cells are silenced when REM sleep-like signs are elicited by pontine carbachol. J Appl Physiol 2002;93:1448-1456.
77. Lechin F, van der Dijs B, Orozco B, Lechin AE, Baez S, Lechin ME, Benaim M, Acosta E, Arocha L, Jimenez V, Leon G, Garcia Z: Plasma neurotransmitters, blood pressure and heart during supine-resting, orthostasis and moderate exercise in severely ill patients: A model of failing to cope with stress. Psychother Psychosom 1996;65:129-136.
78. Lechin F, van der Dijs B, Hernandez G, Orozco B, Rodriguez S, Baez S: Effects of sibutramine on circulating neurotransmitters in healthy subjects. Neurotoxicology 2006;27:184-191.
79. Robertson D, Johnson GA, Robertson RM, Nies AS, Shand DG, Oates JA: Comparative assessment of stimuli that release neuronal and adrenomedullary catecholamines in man. Circulation 1979;59:637-643.
80. Lechin F, van der Dijs B, Orozco B, Lechin ME, Baez S, Lechin AE, Rada I, Acosta E, Arocha L, Jimenez V, Leon G, Garcia Z: Plasma neurotransmitters, blood pressure and heart rate during supine-resting, orthostasis and moderate exercise conditions in major depressed patients. Biol Psychiatry 1995;38:166-173.
81. Lechin F, van der Dijs B, Jakubowicz D, Camero RE, Lechin S, Villa S, Reinfeld B, Lechin ME: Role of stress in the exacerbation of chronic illness. Effects of clonidine administration on blood pressure, norepinephrine, cortisol, growth hormone and prolactin plasma levels. Psychoneuroendocrinology 1987;12:117-129.
82. Lechin F, van der Dijs B: Acute effects of sibutramine administration on the autonomic nervous system in obese subjects. Clin Pharmacol Ther, in press.
83. Lechin F, van der Dijs B, Lechin E: Experimental bases for outlining and anatomical integration model of the central autonomic nervous system; in Lechin F, van der Dijs B, Lechin E (eds): The Autonomic Nervous System: Physiological Basis of Psychosomatic Therapy. Barcelona, Editorial Cientifico-Medica, 1979, pp 23-30.
84. Lechin F, van der Dijs B: Neurochemistry and Clinical Disorders: Circuitry of Some Psychiatric and Psychosomatic Syndromes. Boca Raton, CRC Press, 1989.
85. Lechin F, van der Dijs B, Lechin ME: Concluding remarks; in Lechin F, van der Dijs B, Lechin ME (eds): Neurocircuitry and Neuroautonomic Disorders, Reviews and Therapeutic Strategies. Basel, Karger, 2002, pp 69-74.
86. Lechin F, van der Dijs B, Lechin AE, Orozco B, Lechin ME, Báez S, Rada I, León G, Acosta E: Plasma neurotransmitters and cortisol in chronic illness: role of stress. J Med 1994;25:181-192.
87. Nicod N, Giusti V, Besse C, Tappy L: Metabolic adaptations to dexamethasone-induced insulin resistance in healthy volunteers. Obes Res 2003;11:625-631.
88. Lechin F, van der Dijs B, Amat J, Lechin S: Central neuronal pathways involved in anxiety-like behavior syndrome. Experimental findings. Res Commun Psychol Psychiat Behav 1986;11:113-143.
89. Lechin F, van der Dijs B, Jara H, Orozco B, Baez S, Benaim M, Lechin M, Lechin A: Effects of buspirone on plasma neurotransmitters in healthy subjects. J Neural Transm 1998;105:561-573.
90. Lechin F, van der Dijs B, Jakubowicz D, Camero RE, Villa S, Arocha L, Lechin AE: Effects of clonidine on blood pressure, noradrenaline, cortisol, growth hormone, and prolactin plasma levels in high and low intestinal tone depressed patients. Neuroendocrinology 1985;41:156-162.
91. Lechin F, van der Dijs B, Jakubowicz D, Camero R, Villa S, Lechin E, Gomez F: Effects of clonidine on blood pressure, noradrenaline, cortisol, growth hormone and prolactin plasma levels in low and high intestinal tone subjects. Neuroendocrinology 1985;40:253-261.
92. Lechin F, van der Dijs B: Growth hormone, polycystic ovary syndrome and clonidine test. Fertil Steril 2004;82:765-767.
93. Lechin F, van der Dijs B, Benaim M: Stress versus depression. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:899-950.
94. Zhao Z, Ksiezak-Reding H, Riggio S, Haroutunian V, Pasinetti GM: Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophr Res 2006;84:1-14.
95. Hagg S, Lindblom Y, Mjorndal T, Adolfsson R: High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006;21:93-98.
96. Faulkner G, Cohn TA: Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. Can J Psychiatry 2006;51:502-511.
97. Remington G: Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining? Am J Psychiatry 2006;163:1132-1134.
98. Lechin F, van der Dijs B: Clonidine therapy for psychosis and tardive dyskinesia. Am J Psychiatry 1981;138:390.
99. Lechin F, van der Dijs B. Noradrenergic or dopaminergic activity in chronic schizophrenia? Br J Psychiatry 1981;139:472.
100. Lechin F, Gomez F, van der Dijs B, Lechin E: Distal colon motility in schizophrenic patients. J Clin Pharmacol 1980;20:459-464.
101. Lechin F, van der Dijs B, Gomez F, Lechin E, Oramas O, Villa S: Positive symptoms of acute psychosis: dopaminergic or noradrenergic overactivity? Res Commun Psychol Psychiat Behav 1983;8:23-54.
102. Lechin F, van der Dijs B, Lechin ME: Psychotic syndrome; in Lechin F, van der Dijs B, Lechin ME (eds): Neurocircuitry and Neuroautonomic Disorders. Reviews and Therapeutic Strategies. Basel, Karger, 2002, pp 51-53.
103. Lechin F, van der Dijs B: Noradrenergic hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:777-778.
104. Tassin JP: NE/DA interactions in prefrontal cortex and their possible roles as neuromodulators in schizophrenia. J Neural Transm 1992;36:135-162.
105. Yamamoto K, Hornykiewicz O: Proposal for a noradrenaline hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:913-922.
106. Lohr JB, Jeste DV: Locus ceruleus morphometry in aging and schizophrenia. Acta Psychiatr Scand 1988;77:689-697.
107. van Dongen PA: The human locus coeruleus in neurology and psychiatry. (Parkinson's, Lewy body, Hallervorden-Spatz, Alzheimer's and Korsakoff's disease, (pre) senile dementia, schizophrenia, affective disorders, psychosis). Prog Neurobiol 1981;17:97-139.
108. Dawe GS, Huff KD, Vandergriff JL, Sharp T, O'Neill MJ, Rasmussen K: Olanzapine activates the rat locus coeruleus: in vivo electrophysiology and c-Fos immunoreactivity. Biol Psychiatry 2001;50:510-520.
109. Linner L, Wiker C, Wadenberg ML, Schalling M, Svensson TH: Noradrenaline reuptake inhibition enhances the antipsychoticlike effect of raclopride and potentiates D2-blockage-induced dopamine release in the medial prefrontal cortex of the rat. Neuropsychopharmacology 2002;27:691-698.